US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
JP5489997B2
(en)
|
2007-07-19 |
2014-05-14 |
シマベイ セラピューティクス, インコーポレーテッド |
N-aza cyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of RUP3 or GPRl 19 receptors for the treatment of diabetes and metabolic diseases
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US20110294836A1
(en)
*
|
2008-06-20 |
2011-12-01 |
Metabolex, Inc. |
Aryl gpr119 agonists and uses thereof
|
US8273900B2
(en)
|
2008-08-07 |
2012-09-25 |
Novartis Ag |
Organic compounds
|
WO2010149685A1
(en)
|
2009-06-24 |
2010-12-29 |
Boehringer Ingelheim International Gmbh |
New compounds, pharmaceutical composition and methods relating thereto
|
MX2011013648A
(en)
|
2009-06-24 |
2012-03-06 |
Boehringer Ingelheim Int |
New compounds, pharmaceutical composition and methods relating thereto.
|
ES2497566T3
(en)
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
US8563543B2
(en)
|
2009-10-08 |
2013-10-22 |
Merck Sharp & Dohme Corp. |
Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
EP2485920B1
(en)
|
2009-10-08 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
|
US8557826B2
(en)
|
2009-10-08 |
2013-10-15 |
Merck Sharp & Dohme Corp. |
Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
|
MX2012004990A
(en)
|
2009-10-30 |
2012-06-12 |
Janssen Pharmaceutica Nv |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS.
|
US8486967B2
(en)
*
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
AR080754A1
(en)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
|
JP2013522279A
(en)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Combination of GPR119 agonist and DDP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
EP3381899B1
(en)
|
2010-04-22 |
2021-01-06 |
Vertex Pharmaceuticals Incorporated |
Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
EP2585048B1
(en)
|
2010-06-23 |
2018-04-11 |
CymaBay Therapeutics, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
WO2012006955A1
(en)
*
|
2010-07-14 |
2012-01-19 |
Zhejiang Beta Pharma Inc. |
Compounds for treatment of metabolic disorders
|
MX2013003736A
(en)
|
2010-10-08 |
2013-05-09 |
Cadila Healthcare Ltd |
Novel gpr 119 agonists.
|
RU2606514C2
(en)
|
2010-12-03 |
2017-01-10 |
Эпизайм, Инк. |
Substituted purine and 7-deazapurine compounds
|
KR20130124959A
(en)
|
2010-12-03 |
2013-11-15 |
에피자임, 인코포레이티드 |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
US20120184572A1
(en)
*
|
2011-01-13 |
2012-07-19 |
Metabolex, Inc. |
Aryl gpr119 agonists and uses thereof
|
EP2686312B1
(en)
*
|
2011-03-14 |
2016-08-31 |
Boehringer Ingelheim International GmbH |
N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
TWI572599B
(en)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
SI2705029T1
(en)
|
2011-05-04 |
2019-03-29 |
Rhizen Pharmaceuticals S.A. |
Novel compounds as modulators of protein kinases
|
JP5999177B2
(en)
|
2011-05-04 |
2016-09-28 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Compound for inhibiting cell proliferation of EGFR-activated cancer
|
JP6115962B2
(en)
|
2011-06-27 |
2017-04-19 |
ヤンセン ファーマシューティカ エヌ.ベー. |
1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline derivatives
|
AR087701A1
(en)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
|
EP2838898B1
(en)
|
2012-04-20 |
2017-01-18 |
Advinus Therapeutics Limited |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
EP2841428B1
(en)
|
2012-04-24 |
2018-08-22 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
EP2858986B1
(en)
*
|
2012-06-12 |
2019-10-30 |
Chong Kun Dang Pharmaceutical Corp. |
Piperidine derivatives as gpr119 agonists
|
CA2872216C
(en)
|
2012-06-26 |
2021-07-20 |
Janssen Pharmaceutica Nv |
Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
|
BR112015000459B1
(en)
|
2012-07-09 |
2022-02-08 |
Janssen Pharmaceutica N.V. |
PHOSPHODIESTERASE 10 ENZYME INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION INCLUDING THEM, THEIR PREPARATION PROCESS AND PRODUCT
|
AR091739A1
(en)
|
2012-07-11 |
2015-02-25 |
Elcelyx Therapeutics Inc |
COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK
|
WO2014026198A1
(en)
|
2012-08-10 |
2014-02-13 |
Epizyme, Inc. |
Inhibitors of protein methyltransferase dot1l and methods of use thereof
|
CA2883781A1
(en)
|
2012-09-06 |
2014-03-13 |
Epizyme, Inc. |
Method of treating leukemia
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
AR092924A1
(en)
|
2012-10-09 |
2015-05-06 |
Sanofi Sa |
PIRROLIDINONE DERIVATIVES AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
|
US9980973B2
(en)
|
2012-10-19 |
2018-05-29 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
GB201218862D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
GB201218850D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
GB201218864D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
DK3527563T3
(en)
|
2013-03-12 |
2021-12-06 |
Vertex Pharma |
DNA-PK INHIBITORS
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
AU2014237340C1
(en)
|
2013-03-15 |
2018-11-08 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
WO2014152566A2
(en)
|
2013-03-15 |
2014-09-25 |
Epizyme, Inc. |
Methods of synthesizing substituted purine compounds
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
AU2014258128A1
(en)
*
|
2013-04-25 |
2015-10-29 |
Yuhan Corporation |
Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same
|
DE102013008118A1
(en)
|
2013-05-11 |
2014-11-13 |
Merck Patent Gmbh |
Arylchinazoline
|
CA2912747C
(en)
*
|
2013-06-27 |
2021-05-04 |
Lg Life Sciences Ltd. |
Biaryl derivatives as gpr120 agonists
|
GB201314452D0
(en)
|
2013-08-13 |
2013-09-25 |
Ostara Biomedical Ltd |
Embryo implantation
|
AU2014334554B2
(en)
|
2013-10-14 |
2018-12-06 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
MX363708B
(en)
|
2013-10-14 |
2019-03-29 |
Eisai R&D Man Co Ltd |
Selectively substituted quinoline compounds.
|
RU2675270C2
(en)
|
2013-10-17 |
2018-12-18 |
Вертекс Фармасьютикалз Инкорпорейтед |
Co-crystals and pharmaceutical compositions containing same
|
EA202092627A1
(en)
|
2013-11-18 |
2021-09-30 |
Глобал Блад Терапьютикс, Инк. |
COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
|
MX366297B
(en)
|
2013-11-26 |
2019-07-04 |
Chong Kun Dang Pharmaceutical Corp |
Amide derivatives for gpr119 agonist.
|
BR122022015241B1
(en)
|
2013-12-20 |
2023-09-26 |
Astex Therapeutics Limited |
INTERMEDIATE BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE PREPARATION OF A COMPOUND OF FORMULA (I)
|
CN111393431A
(en)
|
2014-01-06 |
2020-07-10 |
理森制药股份公司 |
Glutaminase inhibitors
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
JO3517B1
(en)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
GB201402277D0
(en)
|
2014-02-10 |
2014-03-26 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
EP3626714A1
(en)
|
2014-02-13 |
2020-03-25 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
SG10201806849WA
(en)
|
2014-02-13 |
2018-09-27 |
Incyte Corp |
Cyclopropylamines as lsd1 inhibitors
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
TW201613860A
(en)
|
2014-02-13 |
2016-04-16 |
Incyte Corp |
Cyclopropylamines as LSD1 inhibitors
|
TW201625605A
(en)
|
2014-04-04 |
2016-07-16 |
賽諾菲公司 |
Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
|
KR20160132887A
(en)
|
2014-04-04 |
2016-11-21 |
사노피 |
Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
|
TW201623286A
(en)
|
2014-04-04 |
2016-07-01 |
賽諾菲公司 |
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
|
BR112016023422A8
(en)
|
2014-04-15 |
2021-07-20 |
Vertex Pharma |
spray-dried dispersion, pharmaceutical composition and its uses, kit and tablet
|
MX2016014308A
(en)
|
2014-05-01 |
2017-01-27 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists.
|
KR102139847B1
(en)
|
2014-05-01 |
2020-07-31 |
노파르티스 아게 |
Compounds and compositions as toll-like receptor 7 agonists
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
TWI687419B
(en)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
Imidazopyridines and imidazopyrazines as LSD1 inhibitors
|
UY36294A
(en)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
|
RS62017B1
(en)
|
2014-09-17 |
2021-07-30 |
Celgene Car Llc |
Mk2 inhibitors and uses thereof
|
GB201501302D0
(en)
|
2015-01-27 |
2015-03-11 |
Ostara Biomedical Ltd |
Embryo implantation
|
PE20180455A1
(en)
|
2015-04-03 |
2018-03-05 |
Incyte Corp |
HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
|
JP6986972B2
(en)
|
2015-06-18 |
2021-12-22 |
エイティナイン バイオ リミテッド |
Substituted 4-benzyl and 4-benzoylpiperidin derivatives
|
CN107847765B
(en)
|
2015-06-18 |
2021-05-04 |
89生物有限公司 |
1, 4-substituted piperidine derivatives
|
EP3310774B1
(en)
|
2015-06-19 |
2020-04-29 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
EP3310771B1
(en)
|
2015-06-19 |
2020-07-22 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
SG10202001219UA
(en)
|
2015-08-12 |
2020-03-30 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
GB201517523D0
(en)
|
2015-10-05 |
2015-11-18 |
Ostara Biomedical Ltd |
Methods and compositions for managing reproduction
|
MA44334A
(en)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
|
CA3021678A1
(en)
|
2016-04-22 |
2017-10-26 |
Incyte Corporation |
Formulations of an lsd1 inhibitor
|
CA3026149A1
(en)
|
2016-06-02 |
2017-12-07 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
PE20190971A1
(en)
|
2016-06-13 |
2019-07-09 |
Glaxosmithkline Ip Dev Ltd |
CHEMICAL COMPOUNDS
|
US10934285B2
(en)
|
2016-06-14 |
2021-03-02 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
EP3493807A1
(en)
|
2016-08-03 |
2019-06-12 |
CymaBay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
CA3038657A1
(en)
|
2016-09-27 |
2018-04-05 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
|
AR110770A1
(en)
|
2017-01-23 |
2019-05-02 |
Cadent Therapeutics Inc |
POTASSIUM CHANNEL MODULATORS
|
AR110988A1
(en)
|
2017-02-21 |
2019-05-22 |
Sanofi Sa |
AZETIDINE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
|
EP3630118A4
(en)
|
2017-05-23 |
2021-03-31 |
MEI Pharma, Inc. |
Combination therapy
|
MA49566A
(en)
|
2017-07-11 |
2020-05-20 |
Vertex Pharma |
CARBOXAMIDES USED AS SODIUM CHANNEL INHIBITORS
|
MA49921A
(en)
|
2017-08-14 |
2021-05-12 |
Mei Pharma Inc |
POLYTHERAPY
|
AU2018346597B2
(en)
|
2017-10-06 |
2023-07-13 |
Forma Therapeutics, Inc. |
Inhibiting Ubiquitin Specific Peptidase 30
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
CN113227103A
(en)
|
2018-09-18 |
2021-08-06 |
尼坎医疗公司 |
Trisubstituted heteroaryl derivatives as SRC homologous-2 phosphatase inhibitors
|
BR112021003620A2
(en)
|
2018-10-05 |
2021-05-18 |
Forma Therapeutics, Inc. |
Fused pyrrolines that act as specific protease inhibitors for ubiquitin 30 (usp30)
|
SG11202107615TA
(en)
|
2019-01-18 |
2021-08-30 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
AR119731A1
(en)
|
2019-05-17 |
2022-01-05 |
Novartis Ag |
NLRP3 INFLAMASOME INHIBITORS
|
WO2021004467A1
(en)
*
|
2019-07-08 |
2021-01-14 |
南京明德新药研发有限公司 |
Compound as porcupine inhibitor and use thereof
|
CA3164134A1
(en)
|
2019-12-06 |
2021-06-10 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofurans as modulators of sodium channels
|
MX2022014505A
(en)
|
2020-05-19 |
2022-12-13 |
Kallyope Inc |
Ampk activators.
|
WO2021263039A1
(en)
|
2020-06-26 |
2021-12-30 |
Kallyope, Inc. |
Ampk activators
|
IL305165A
(en)
|
2021-02-19 |
2023-10-01 |
Sudo Biosciences Ltd |
Tyk2 inhibitors and uses thereof
|
IL308953A
(en)
|
2021-06-04 |
2024-01-01 |
Vertex Pharma |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
|
CN117813098A
(en)
*
|
2021-08-13 |
2024-04-02 |
苏州亚盛药业有限公司 |
Methods of treating diseases or conditions
|
CN113480522A
(en)
*
|
2021-08-19 |
2021-10-08 |
守恒(厦门)医疗科技有限公司 |
Novel phenylpyrazole derivative and application thereof in hypoglycemic drugs
|